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MICRO- AND NANOPARTICULATE
CANCER VACCINES: A VISION
FOR THE FUTURE
Micro/nanoparticles show promise for immunotherapy against
cancer.

By Lipika Chablani, Ph.D., St. John Fisher College

F

ormulation scientists are constantly challenged with unique
opportunities to deliver chemotherapeutic drug molecules
to cancer patients. With the
growing rate of cancer diagnoses, new therapies are being
introduced to pave their way to
the market. Along with drug delivery, these
formulation approaches are being screened
for formulation, design, and development of
cancer vaccines. Can a vaccine be formulated to obtain a protective or therapeutic
immune response against cancer?
Research proves that micro/nanoparticles
loaded with unique cancer antigens and decorated with immunostimulatory molecules
are capable of activating the immune system
against cancer. Priming the immune system
provides a specific cytotoxic effect against
the cancer cells. Thus, these microparticulate cancer vaccines activate the immune
system and also limit the adverse effects on
the healthy cells as seen with chemotherapeutic agents. Several research studies in

this direction are progressing to promising
preclinical outcomes.

CANCER VACCINES AND
IMMUNOTHERAPY
The term cancer refers to about 200 diseases
that share two common characteristics: an
uncontrolled growth of cells and the ability
to invade and damage normal tissues either
locally or at distant sites in the body. Current
advances in diagnostic methods allow health
professionals to diagnose several cancer
patients early and provide medical interventions. With the advent of chemotherapy in
the 1940s, there was an increasing need
for drug delivery systems/formulations for
these relatively toxic drug molecules. Several
of these chemotherapeutic drug molecules
are given intravenously and are associated
with systemic adverse effects. Most of
these chemotherapeutic drugs are limited
by virtue of their dose-related toxicity, leaving
the patient to move on to an alternative chemotherapeutic regimen. Apart from chemotherapy, surgical removal of tumor masses

and elimination of solid tumors via radiation
is also commonly employed. However, all
these methods are significantly invasive and
debilitate the patient, impacting the quality
of life. Additionally, many patients undergo
a relapse and must revisit these challenges
all over again.
Considering the drawbacks of chemotherapy, surgery, and radiation therapy, patients
and health practitioners often seek noninvasive alternative therapies. A promising alternative is immunotherapy. Immunotherapy
involves training patients’ own immune systems to fight against cancer and eliminate
it. These immunotherapeutic approaches
include application of various kinds of cancer
vaccines to prime the immune system
against cancer. Many ongoing preclinical
and clinical studies aim to achieve a successful cancer vaccine.
Formulating a cancer vaccine is much
more challenging than formulating an infectious disease vaccine. A cancer vaccine is
against a self-cell that has mutated and
become cancerous. Thus, it is important to
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prime the immune system judiciously to
ensure an attack against cancer cells only
and not healthy cells, which may resemble
these cancerous cells in several aspects.
Additionally, each cancer patient may be
unique with a variable set of mutations
requiring an individualized therapy to gain
maximum efficacy. All these factors make

formulation, design, and development of a
cancer vaccine challenging and provide an
opportunity for researchers to explore various vaccine delivery systems. These vaccine
delivery systems can enable us to prime
the immune cells with unique tumor-associated antigens (TAAs) that are expressed
only by the tumor cells and thus generate

an immune response against the cancer. To
further boost the immune response generated by the vaccine, an adjuvant (an immunostimulant) is included in the formulation.
Upon generation of the immune response,
if the vaccine is capable of inducing the
memory cells of the immune system to
remember the cancer antigens, the benefits
will be multifold. Such memory immune
responses are beneficial when the cancer
relapses. Unlike conventional therapies,
immunotherapy can potentiate the immune
response against a relapsed tumor (if it
expresses the same antigens) and eliminate
it before it forms a mass. Thus, these cancer
vaccines can provide long-term protection
versus temporary relief.

MICRO- AND NANOPARTICLES AS
CANCER VACCINES
In the last decade, several preclinical studies have explored micro/nanoparticles for
immunotherapeutic applications. These
micro/nanoparticles have been formulated
with different polymers, lipids, proteins, and
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Figure 1: Graphical representation of a microparticulate cancer vaccine. Upon administration of the vaccine microparticles, the dendritic cells are stimulated releasing inﬂammatory and/or anti-inﬂammatory cytokines. These
activated dendritic cells are then capable of activating humoral (B cells) and cellular (T cells) adaptive immune
responses to inhibit tumor growth.

adjuvants. Examples of such polymers, lipids,
and proteins include cyclodextrins, celluloses, phospholipids, poly (lactic-co-glycolic)
acid (PLGA), and albumin.1-4 Formulation scientists have employed techniques like spray
drying and coacervation to prepare these particulate delivery systems, resulting in an optimized and reproducible formulation. These
micro- and nanoparticles may either encapsulate the vaccine antigens (tumor-specific
antigens) or exist as a matrix of the polymer
embedded with the vaccine antigens. The
formulation design permits the inclusion of
adjuvants to boost the immune response.
Adjuvants like interleukins, GM-CSF, alum,
and CpG have been evaluated with such
vaccines.
Irrespective of composition, these micro/
nanoparticles are within the average size
range of 100 nm to 5 μm. This unique size
range allows these micro/nanoparticles to
mimic the infectious disease agents like
bacteria/viruses, thus allowing the dendritic
and macrophage cells, in vivo, to phagocytose them preferentially. Upon phagocytosis,
the particles are digested by the cellular
enzymes, and the antigens are expressed by
the dendritic cells via the major histocompatibility complexes (major histocompatibility
complex [MHC] I or II). These dendritic cells
are capable of releasing immunostimulatory cytokines to activate both innate and
adaptive immune systems. The adaptive

16 AAPS NEWSMAGAZINE

| MAR ‘16

immune system responds specifically to
the antigens expressed by the dendritic cells
and prepares an assault against any cancer
cells expressing these antigens (Figure 1).
Multiple boosters of these microparticulate
vaccines induce a series of immunostimulatory responses and assist in eliminating
the tumor burden. The results from preclinical studies in this field depict that these
micro/nanoparticulate vaccines are capable of generating tumor-specific adaptive
immune responses and lead to the shrinkage of tumor mass extending the life span
of diseased animals.5-8 These results are
promising and merit further investigation to
prepare a cancer vaccine.
Such particulate delivery systems include
a range of nanocarriers including liposomes,
virus-like particles, virosomes, polymeric particles, and nanoemulsions.9 Here are some
of the notable advancements in the field
of immunotherapy using these individual
nanocarriers:

Liposomes
Liposomal delivery systems consist of a
phospholipid bilayer structure with an aqueous core, thereby accommodating both
hydrophilic and lipophilic bioactive molecules,
either by encapsulating them or embedding
them in the bilayers respectively. DepoVax is
an example of such a liposome-in-oil emulsion composed of cancer antigens and an

adjuvant. The DepoVax platform includes
liposomes containing cancer antigens and
Montanide ISA51 VG as the adjuvant in the
oil phase. This system has been evaluated
under phase 1 clinical trials and has been
shown to be safe and capable of inducing
immune response against ovarian cancer.
Additional clinical studies using this platform are ongoing to evaluate the safety
and immune response of the vaccine with
low dose cyclophosphamide against ovarian
cancer. Similarly, Tecemotide (Stimuvax or
BLP25) was another liposomal cancer vaccine that paved its way through the phase 3
clinical trials. The vaccine included the MUC1
antigen, which is overexpressed by several
cancers such as lung, breast, prostate, and
colorectal. Along with the antigen, the vaccine consisted of monophosphoryl lipid A as
the adjuvant. The preclinical and early clinical
studies provided promising results; however, the recent phase 3 results evaluating
the application of the vaccine against nonsmall-cell lung cancer were unable to meet
the primary outcomes of the study. Further
evaluation of the vaccine candidate is under
discussion and may need a new direction.
Other significant advancements with
liposomal vaccine delivery include use of
pegylated liposomes to enhance the circulation time of these delivery systems for an
improved immune response. Cationic liposomes and temperature- and pH-sensitive
liposomes have been explored to augment
the immune response generated by such
liposomal cancer vaccines. Thus, combination of liposomal vaccine delivery systems
along with the adjuvants and surface modifications are some of the key developments
in this area of research.

Virus-like Particles and Virosomes
Both virus-like particles (VLPs) and virosomes
provide a unique particulate structure similar to viruses, thus making them inherently
immunogenic as a vaccine carrier. The viral
genome is missing in these structures,
rendering them noninfectious and safe for
prophylactic applications.
VLPs have been successfully used to
administer human papilloma virus (HPV) vaccine. These vaccines contain VLPs made of

only the major HPV coat or capsid protein
L1. Cervarix and Gardisil are two of such
VLP-based cancer vaccines that have been
developed and commercialized. Cervarix
is a bivalent and Gardisil is a quadrivalent
vaccine containing either two (HPV 16/18)
or four (HPV 16/18/6/11) L1 recombinant
proteins. Findings from the clinical trials and
use of these vaccines in the past few years
have established their safety and efficacy in
protection against cervical cancer caused
by HPV. Both these vaccines are used prophylactically and function by generation
of neutralizing antibodies against the viral
strains. Thus, the application of such VLPbased cancer vaccines is limited to cancers
caused by viruses and vaccines intended for
prophylactic applications.
Similarly, virosomes have gained significance as a vaccine carrier for infectious diseases such as influenza (Inflexal) and hepatitis A (Epaxal). Virosomes are unilamellar lipid
viral vesicles comprised of phospholipids and
glycoproteins acting as antigens for induction
of immune response. These characteristic
features allow them to mimic the infectious
disease agents and generate a strong cellular immune response. Immunopotentiating
reconstituted influenza virosomes (IRIVs) are
the most commonly used virosomes against
infectious diseases. The IRIVs have been
evaluated in preclinical studies as a cancer
vaccine delivery system against melanoma
and breast cancer as well. Further, using
a similar approach, another class of virosomes—the Sendai virosomes—has been
developed using the Sendai viruses. The
viral envelope of Sendai viruses, used for
these virosomes, hosts two types of glycoproteins, hemagglutinin-neuraminidase and
the fusion protein. These two glycoproteins
assist the virosomes to bind to the hostcell surface and eventually fuse into their
cell membranes. These properties make
Sendai virosomes a suitable nanocarrier for
delivery of bioactive molecules for cancer
immunotherapy.

have been used as drug delivery systems as
they are capable of targeting and reaching
biological sites, which are otherwise inaccessible. Such particulate systems have been
successfully used to deliver chemotherapeutic drugs. Abraxane (human albumin-bound
paclitaxel nanoparticle) is a good example of
such a Food and Drug Administration (FDA)
approved commercial nanoparticulate delivery system used for the treatment of breast,
non-small-cell lung, ovarian, and pancreatic
cancer. Researchers have attempted to translate these albumin-incorporating nanoparticulate delivery systems to prepare a particulate
cancer vaccine.4,7,10
A variety of polymeric particles have
been formulated and evaluated for antigen
delivery and potential use as a cancer vaccine. Some of the most commonly studied
polymers for this purpose include PLGA,
polylactide (PLA), albumin, gelatin, chitosan, and cyclodextrin. The polymers are
preferentially biodegradable, nontoxic, and

nonimmunogenic to serve as a carrier. Further, these polymeric particles provide the
following advantages:
1) Protection of the cancer antigens (often
susceptible to systemic degradation)
2) Enhanced uptake and presentation of
the antigens via the MHC pathway
3) Sustained release of the antigens to
obtain a prolonged effect of the vaccine
PLGA is one of the extensively studied polymers for immunotherapy and is
also approved by FDA for drug delivery in
humans. Research findings suggest that
PLGA particles are well recognized by the
dendritic cells and lead to effective antigen
presentation and upregulation of inflammatory cytokines responsible for induction of
cellular immune response. These particles
also possess adjuvant-like properties, boosting the immune response further. However,
the formulation of PLGA particles involves
use of organic solvents and higher temperatures, which may not be suitable for all the

Polymeric Particles
Micro- and nanoparticulate delivery systems
have been formulated using both natural and
synthetic polymers. Such polymeric particles
MAR ‘16 | AAPS NEWSMAGAZINE 17

MICRO- AND NANOPARTICULATE CANCER VACCINES: A VISION FOR THE FUTURE

antigens and pose a limitation on scalability
of these vaccine carriers.
As an alternative to synthetic polymers
(PLGA and PLA), natural polymers like albumin and gelatin have been explored due to
their inherent biocompatibility and safety
profiles. The techniques required to formulate particles using these polymers do not
involve any organic solvents and can be
easily scaled up. Additionally, these techniques do not pose any risk to the biological
structure of the antigens being loaded in
the carrier. Research findings have established that particles made of these natural polymers are capable of protecting and
delivering their cargo to result in an immune
response against the variety of in vivo cancer
models. Furthermore, there is a potential of
crosslinking these polymers (albumin cross
linked with glutaraldehyde) to obtain a robust
sustained-release delivery vehicle, which

can be administered via oral, transdermal, or
subcutaneous route of delivery. The preclinical results from these particulate delivery
systems confirm the potential of their use
as carriers for cancer vaccines.

LESSONS LEARNED AND VISION
FOR THE FUTURE
The preclinical and clinical outcomes of
micro/nanoparticulate cancer vaccines are
encouraging, yet additional studies are
required in this direction to establish their
scalability, safety, and efficacy. Some of the
major challenges associated with micro/
nanoparticulate vaccines are attributed to
their biodegradability, stability, and toxicity.
The choice of polymers, proteins, and adjuvants is vital to ensure these ingredients
can be cleared from the system and do not
pose any toxicity issues once digested at
the cellular level. Stability profiles of these

antigen-containing micro/nanoparticles has
also been a concern, and techniques like
lyophilization and spray drying are evaluated
to stabilize these antigen formulations. Furthermore, it is imperative to be able to scale
up these preparations, if additional clinical
studies are warranted. As this approach is
still in its infancy, researchers are exploring
ways to optimize such cancer vaccines to
induce stronger and longer -lasting immune
responses that are capable of generating a
memory response to avoid potential relapse
of the cancer. Considering the scope of this
approach to achieve a competent therapeutic cancer vaccine, it is promising to look
forward to the advances researchers will
be making in this direction in the upcoming
decade.

DISCUSSION
POINT
We want to know your opinion!
Please discuss the following question
with your colleagues via the AAPS Blog.
To find the blog entry associated with this
article, visit http://aapsblog.aaps.org/tag/
aaps-newsmagazine.
Which other alternative approaches can
benefit formulation scientists to boost the
immune response of such micro/nanoparticulate cancer vaccines?
Learn more about the AAPS Formulation
Design and Development section; visit the
section’s webpage at www.aaps.org/FDD.
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